Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $170.75M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
KRRO Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Korro Bio, Inc.NASDAQ: KRRO
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 11.6M shares rose 23.6% year over year, ahead of the +8.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 23.5% from the prior quarter. Over 3 fiscal years it compounded at +232.8% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +23.6% holds above the trailing-twelve-month pace of +8.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 9.4M USD
- Year-over-year change
- +5.3%
- 4-year CAGR
- +20.6%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.4M | +5.3% |
| FY2024 | 2024-12-31 | 8.92M | +483.4% |
| FY2023 | 2023-12-31 | 1.53M | +499.6% |
| FY2022 | 2022-12-31 | 255K | -94.3% |
| FY2021 | 2021-12-31 | 4.45M | — |
Weighted Avg Shares vs competitors
How KRRO compares with its peers on the latest reported figures
- KRRO's LTM Mar 2026 weighted avg shares of 9.94M shares is the lowest of the 11 companies compared; the peer median is 61.39M shares.
- Its year-over-year change of +8.7% is the 7th highest of 9, against a peer median of +18.4%.
- Over three fiscal years its annual growth of +232.8% compares with a peer median of +33.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 161.69M | +14.3% | +41.6% | |
| LTM Mar 2026 | 98.99M | +37.1% | +23.4% | |
| LTM Mar 2026 | 88.66M | -7.8% | +3.7% | |
| LTM Mar 2026 | 78.18M | +22.5% | +41.5% | |
| LTM Mar 2026 | 62.93M | +26.5% | +26.3% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | 59.85M | +25.2% | +47.9% |
| LTM Mar 2026 | 31.49M | — | +63.9% | |
| LTM Mar 2026 | 29.75M | +10.2% | +4.1% | |
| LTM Mar 2026 | 20.78M | +1.0% | +1.1% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | 19.77M | — | +92.6% |
| LTM Mar 2026 | 9.94M | +8.7% | +232.8% | |
| Peer median (excluding KRRO) | 61.39M | +18.4% | +33.9% | |
Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.07M | 0 | 0 | 2.27M | 6.39M |
| Cost of Revenue | 3.84M | 0 | 0 | 0 | 4.28M |
| Gross Profit | 10.23M | 0 | 0 | 2.27M | 2.11M |
| Gross Margin | 72.7% | — | — | 100.0% | 33.0% |
| Research & Development | 59.32M | 42.2M | 57.25M | 63.64M | 65.58M |
| Selling, General & Admin | 34.93M | 16.8M | 36.54M | 30.55M | 28.16M |
| Operating Expenses | 94.26M | 59M | 84.53M | 94.18M | 89.45M |
| Depreciation & Amortization | 3.84M | 2.51M | 3.63M | 3.57M | 4.28M |
| EBITDA | (80.07M) | (56.49M) | (80.9M) | (88.35M) | (83.06M) |
| EBITDA Margin | -569.1% | — | — | -3890.1% | -1299.5% |
| Operating Income | (84.03M) | (59M) | (84.53M) | (91.91M) | (87.34M) |
| Operating Margin | -597.3% | — | — | -4047.1% | -1366.4% |
| Interest Income | 397K | 947K | 0 | 0 | 0 |
| Interest Expense | 764K | 118K | 0 | 0 | 0 |
| Other Income / Expenses | (640K) | 976K | 3.39M | 8.47M | (29.28M) |
| Income Before Tax | (84.67M) | (58.02M) | (81.15M) | (83.44M) | (116.62M) |
| Pre-Tax Margin | -601.9% | — | — | -3674.2% | -1824.5% |
| Income Tax Expense | 15K | 10K | 27K | 141K | 637K |
| Net Income | (84.69M) | (58.03M) | (81.17M) | (83.58M) | (117.26M) |
| Net Margin | -602.0% | — | — | -3680.4% | -1834.5% |
| EPS (Basic) | (4.94) | (227.58) | (53.09) | (9.37) | (12.48) |
| EPS (Diluted) | (4.94) | (227.42) | (53.08) | (9.37) | (12.48) |
| Weighted Avg Shares | 4.45M | 255K | 1.53M | 8.92M | 9.4M |
| Weighted Avg Shares (Diluted) | 4.45M | 255.17K | 1.53M | 8.92M | 9.4M |
Korro Bio, Inc.
NASDAQ:KRRO
Intrinsic Alpha fair value
Locked
Current Price
$12.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.